Myasthenia Gravis Clinical Trial
Official title:
Investigation of the Effects of Proprioceptive Neuromuscular Facilitation Exercises on Fatigue, Muscle Strength and Functional Parameters in Patients With Myasthenia Gravis
The goal of this clinical trial is to investigate of the effects of proprioceptive neuromuscular facilitation exercises on fatigue, muscle strength and functional parameters in patient with Myasthenia Gravis. The main questions it aims to answer are: - Do proprioceptive neuromuscular facilitation exercises reduce fatigue in patients with Myasthenia Gravis? - Do proprioceptive neuromuscular facilitation exercises increase muscle strength in patients with Myasthenia Gravis? - Do proprioceptive neuromuscular facilitation exercises improve functional parameters in patients with Myasthenia Gravis? - How well can patients with Myasthenia Gravis tolerate proprioceptive neuromuscular facilitation exercises? Participants will be divided into 2 groups as control group and exercise group with block randomization method. In this single-blind randomized controlled study, the participants in the control group will be placed on a waiting list without any intervention during the 6-week study period and at the end of the study, the interventions applied to the exercise group will be applied exactly the same. Proprioceptive neuromuscular facilitation exercises will be applied to the exercise group 3 days a week, 1 hour a day for 6 weeks. Individuals will be evaluated at the beginning and at the end of the study. Researchers will compare exercise and control group to see if there are effects of proprioceptive neuromuscular exercises patients with Myasthenia Gravis.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | December 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Volunteering to participate in the study - Being between the ages of 18-65 - It must be confirmed by the Neurologist that the patient has been diagnosed with Achr+ generalized Myasthenia Gravis and has been in a stable condition for the last 6 months. - Being in class II or III according to the American Myasthenia Gravis Foundation Clinical Classification Exclusion Criteria: - Having a cognitive problem or having a Mini Mental Test score below 24 - Having had a myasthenic crisis within the last month, - Change in the type and dose of medical treatment within the last month - Having another cardiorespiratory, metabolic, systemic, orthopedic and neurological disease in addition to Myasthenia Gravis - Having participated in any physiotherapy program for the last 6 months - Having undergone pregnancy, birth or surgical operation in the last 6 months. |
Country | Name | City | State |
---|---|---|---|
Turkey | Hacettepe University Faculty of Physical Therapy and Rehabilitation | Ankara | Altindag |
Lead Sponsor | Collaborator |
---|---|
Hacettepe University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | chalder fatigue scale | It is an easy, fast and useful scale that evaluates fatigue through self-report. The final version of the scale consists of a total of 11 items, including a 7-item physical fatigue subsection and a 4-item mental fatigue subsection. The individual is asked to respond to the statements using a four-point Likert scale (less than usual, as much as usual, more than usual, much more than usual). Each item is scored between 0-3 and the total score varies between 0-33. | baseline and immediately after the intervention | |
Primary | Fatigue Impact Scale | It is a multidimensional scale that evaluates the physical, cognitive and social effects of fatigue. The scale consists of a total of 40 questions: 10 questions for the physical effects subscale, 10 questions for the cognitive effects subscale, and 20 questions for the social effects subscale. Individuals fill out the scale by taking their last month into consideration. All questions are scored from "0" (no problem) to "4" (very big problem). Higher scores indicate increased degree of fatigue. | baseline and immediately after the intervention | |
Primary | fatigue severity scale | It is a self-report scale consisting of 9 items that evaluates the degree of fatigue severity in the last week. For each item, the patient marks the most appropriate statement on a 7-point Likert scale ranging from 7=strongly agree to 1=strongly disagree. The scores obtained from each item are added up and the total value is divided by 9. | baseline and immediately after the intervention | |
Primary | Surface electromyography | Surface electromyography measurements will be performed to measure the electrical signals coming from the muscles to determine the fatigue of the muscles. It has been shown in the literature that fatigue can be measured by power spectrum analysis in neuromuscular diseases. For this purpose, surface electromyography electrodes will be placed on the vastus lateralis muscle and the middle part of the deltoideus muscle and the participants will be asked to make maximum isometric contraction for 30 seconds. Electromyography signals will be analyzed and median frequencies between 0-5 seconds and 25-30 seconds will be determined and recorded. Wireless surface electromyography sensors and portable data acquisition system will be used to record and store measurements (Delsys (Delsys Inc. Natick, Massachusetts, USA)). | baseline and immediately after the intervention | |
Primary | Six Minute Walk Test | It will be applied to evaluate functional capacity in accordance with the guidelines of the American Thoracic Society. In this test, the participant is walked down a 30-meter straight corridor. Participants are asked to walk for 6 minutes at the maximum speed they can walk during the test. The total distance walked is recorded. The distance walked per minute will also be recorded during this test. From these data, physical fatigue will be calculated according to the fatigue ambulatory index formula. | baseline and immediately after the intervention | |
Secondary | muscle strength | The upper extremity, lower extremity and neck muscles of the participants will be evaluated using a digital hand dynamometer (Lafayette Manual Muscle Tester Model 01165, Lafayette Instrument Company, Lafayette, IN, USA). Muscle strength measurements will be evaluated by applying a breaking test to measure maximum muscle strength, with a digital hand dynamometer placed between the patient's evaluating area and the physiotherapist's hand, depending on the principles and positions of manual muscle testing. In the upper extremities; shoulder flexors, shoulder extensors, shoulder abductors, elbow flexors and extensors, in the lower extremities; hip flexors, hip extensors, hip abductors, knee flexors and extensors will be evaluated. In the cervical region, both flexor and extensor muscle groups will be evaluated and recorded. Three measurements will be made for all muscles and the average value will be recorded. | baseline and immediately after the intervention | |
Secondary | functional capacity | Two timed performance tests will be used: the 30-second sit-to-stand test and the stair-climbing test. In the 30-second sit-to-stand test, the participant is asked to sit on a standard chair for 30 seconds. The participant is asked to sit and stand as many times as possible throughout the session. The number of repetitions performed within a 30-second period will be recorded. In the stair climbing test, the participant will be asked to climb 10 standard steps as quickly as possible. The time it takes to climb 10 steps will be recorded in seconds. Both methods are used to determine functional capacity in patients with Myasthenia Gravis. | baseline and immediately after the intervention | |
Secondary | Myasthenia Gravis-Activities of Daily Living Scale | It is a self-report scale consisting of eight items. It is designed to evaluate the functional performance of daily living activities impaired due to Myasthenia Gravis. Two of the items in the scale consist of ocular, three bulbar, one respiratory, and two extremity-related activities. Each item is rated from 0 to 3, and the total score range is 0 to 24. High scores indicate low independence. | baseline and immediately after the intervention | |
Secondary | Myasthenia Gravis Quality of Life Scale | It is a self-report scale consisting of fifteen items. It is designed to evaluate the change in quality of life due to Myasthenia Gravis. Items in the scale are scored between 0 and 4, and the total score range is 0-60. The higher the score, the worse the patient's perceived quality of life. | baseline and immediately after the intervention | |
Secondary | Myasthenia Gravis Composite Scale | It is a scale developed to determine disease severity, applied and scored by healthcare professionals. Myasthenia Gravis Composite Scale scoring is created by combining parts of three scales. Ocular evaluation was obtained from the Quantitative Myasthenia Gravis Scale, bulbar and neck flexion evaluations were obtained from the Myasthenia Gravis Activity of Daily Living Scale, and muscle strength tests were obtained from the Manual Muscle Test scale. Total score varies between 0-50. Higher scores indicate increased disease severity. | baseline and immediately after the intervention | |
Secondary | visual analog scale | How well patients can tolerate Proprioceptive Neuromuscular Facilitation Exercises and their satisfaction with the treatment will be evaluated with 4 visual analog scales. Visual Analogue Scale consists of a 100 mm line. At each end of the line, there are two opposing statements about the situation to be evaluated. The participant is asked to mark the point on the visual analog scale line that best reflects his or her feelings. The point marked by the participant is measured in cm or mm from the end point with the help of a ruler. | immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05039190 -
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
|
Phase 3 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT01727193 -
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
|
Phase 3 | |
Completed |
NCT00285350 -
Mycophenolate Mofetil in Myasthenia Gravis
|
Phase 3 | |
Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
Completed |
NCT05694234 -
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
|
||
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Not yet recruiting |
NCT04965987 -
Oxaloacetate in Myasthenia Gravis
|
Phase 1 | |
Not yet recruiting |
NCT05095103 -
Immune Profiles in Myasthenia Gravis
|
||
Completed |
NCT02774239 -
A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)
|
Phase 3 | |
Terminated |
NCT02102594 -
Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
|
Phase 2 | |
Completed |
NCT02066519 -
Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis
|
N/A | |
Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
Terminated |
NCT01828294 -
Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis
|
Phase 1 | |
Terminated |
NCT00727194 -
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
|
Phase 2 | |
Completed |
NCT04590716 -
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
|
||
Recruiting |
NCT04837625 -
Study of Myasthenic Crisis in China
|
||
Not yet recruiting |
NCT01469858 -
Perception and Multisensory Integration in Neurological Patients Using fMRI
|
N/A | |
Completed |
NCT05408702 -
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
|
||
Completed |
NCT03205306 -
Myasthenia Gravis and Psyche
|